TECHNOLOGY OFFER

Combinatorial of markers to improve the diagnosis of pancreatic cancer

BIOTECHNOLOGY & HEALTH SCIENCE

Nowadays, pancreatic cancer is the fourth leading cause of cancer death in western countries. When diagnosed, it is usually found in very advanced state and it doesn't respond well to current therapies. The current detection techniques do not differentiate it from other benign diseases which involves to false positives. It required a marker that allows a differential diagnosis between pancreatic cancer and chronic pancreatitis.

TECHNOLOGY DESCRIPTION

This technology consists in a differential diagnosis of pancreatic cancer and chronic pancreatitis. Specifically, the present invention relates to a combination of existing markers (CA19-9, CEA) with other molecules IGF-1 and albumin to achieve an algorithm, which allows a more efficient diagnosis.

APPLICATION AND TARGET MARKET

This technology can be applied in diagnostic kits of pancreatic cancer with simultaneous determination of different parameters.

The target market encompasses the biopharmaceutical sector; this sector is growing despite the economic crisis, and the therapy against pancreatic cancer.

COMPETITIVE ADVANTAGES

- More efficient diagnosis of pancreatic cancer compared to chronic pancreatitis.
- Combination with improves the specificity and sensitivity of the current markers.
- Easy to implement it in a routine clinical.

TIME-TO-MARKET
The technology is patented and under development

DEAL SOUGHT
License agreement
Development agreement with a company

RESEARCH GROUP
Biochemistry of cancer

CONTACT
Unitat d'Innovació i Transferència de l'RDI

Oficina Tècnica de Recerca i Transferència (OTRiT)
—
UdG
transferencia@udg.edu
+34 972 41 81 47